RNA测序分析识别肌少症诊断的潜在生物标志物
本研究结合综合临床数据与外周血单核细胞mRNA测序分析,纳入114名66-94岁老年人(52例肌少症、62例正常),探索肌少症诊断生物标志物。RNA-seq检测到6个差异表达基因(FAR1、GNL2、HERC5、MRPL47、NUBP2、S100A11)及2个功能模块枢纽基因(MYH9、FLNA)。联合步态长度、HERC5、S100A11和FLNA的最佳模型在验证队列中AUC达0.91(95%CI:0.78-0.95),加入BMI后AUC达0.95(95%CI:0.84-0.99)。
要点
- RNA-seq检测到6个差异表达基因及2个功能模块枢纽基因(MYH9、FLNA)。
- 联合步态长度、HERC5、S100A11和FLNA的模型验证队列AUC为0.91(95%CI:0.78-0.95)。
核心结论
- 研究发现肌少症诊断的潜在生物标志物,进一步优化可能推动未来临床实际应用。
研究设计与样本
- 研究纳入114名66-94岁老年人,其中52例按2019年亚洲肌少症工作组共识诊断为肌少症,62例为正常老年人。
- 研究结合综合临床数据与外周血单核细胞mRNA测序(RNA-seq)分析,并构建风险预测模型。
主要发现
- RNA-seq分析检测到6个差异表达基因(FAR1、GNL2、HERC5、MRPL47、NUBP2、S100A11)。
- 基因集富集分析检测到2个功能模块(即枢纽基因MYH9和FLNA)。
- 联合步态长度、HERC5、S100A11和FLNA的最佳模型在验证队列中AUC达0.91(95%CI:0.78-0.95)。
- 加入BMI后模型AUC达0.95(95%CI:0.84-0.99);3个基因的定量PCR结果与RNA-seq观察到的趋势一致。
关键数值与推荐
- 肌少症诊断依据2019年亚洲肌少症工作组共识,共52例诊断为肌少症。
- 最佳模型(步态长度+HERC5+S100A11+FLNA)验证队列AUC=0.91(95%CI:0.78-0.95)。
- 加入BMI后模型验证队列AUC=0.95(95%CI:0.84-0.99)。
临床怎么用
- 研究发现潜在生物标志物,进一步优化可能推动未来临床实际应用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcopenia is a geriatric disease associated with increased mortality and disability. Early diagnosis and intervention are required to prevent it. This study investigated biomarkers for sarcopenia by using a combination of comprehensive clinical data and messenger RNA-sequencing (RNA-seq) analysis obtained from peripheral blood mononuclear cells. We enrolled a total of 114 older adults aged 66-94 years (52 sarcopenia diagnosed according to the Asian Working Group for Sarcopenia 2019 consensus and 62 normal older people). We used clinical data which were not included diagnosis criteria of sarcopenia, and stride length showed significance by logistic regression analysis (Bonferroni corrected p = .012, odds ratio = 0.14, 95% confidence interval [CI]: 0.05-0.40). RNA-seq analysis detected 6 differential expressed genes (FAR1, GNL2, HERC5, MRPL47, NUBP2, and S100A11). We also performed gene-set enrichment analysis and detected 2 functional modules (ie, hub genes, MYH9, and FLNA). By using any combination of the 9 candidates and basic information (age and sex), risk-prediction models were constructed. The best model by using a combination of stride length, HERC5, S100A11, and FLNA, achieved a high area under the curve (AUC) of 0.91 in a validation cohort (95% CI: 0.78-0.95). The quantitative PCR results of the 3 genes were consistent with the trend observed in the RNA-seq results. When BMI was added, the model achieved a high AUC of 0.95 (95% CI: 0.84-0.99). We have discovered potential biomarkers for the diagnosis of sarcopenia. Further refinement may lead to their future practical use in clinical use.
引用
- Furutani M, Suganuma M, Akiyama S, et al. RNA-Sequencing Analysis Identification of Potential Biomarkers for Diagnosis of Sarcopenia. J Gerontol A Biol Sci Med Sci. 2023. PMID: 37347997. doi:10.1093/gerona/glad150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。